FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial.

MLA

Sprinzl, Martin, et al. “FRI-208-Predictors of Treatment Response during Addition of Pegylated Interferon Alfa-2a to an Onging Nucleos (t)Id Treatment in Chronic Hepatitis B: Results from the PADD-ON Trial.” Journal of Hepatology, vol. 70, Apr. 2019, p. e485. EBSCOhost, https://doi.org/10.1016/S0618-8278(19)30953-3.

APA

Sprinzl, M., Grambihler, A., Teuber, G., Antoni, C., Zeuzem, S., Discher, T., Cornberg, M., Berg, T., Loehr, H., Tacke, F., Lammert, F., Schott, E., Berg, C., Zizer, E., Heyne, R., Spengler, U., Geisler, F., Thimme, R., Pathil, A., & Klinker, H. (2019). FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial. Journal of Hepatology, 70, e485. https://doi.org/10.1016/S0618-8278(19)30953-3

Chicago

Sprinzl, Martin, Annette Grambihler, Gerlinde Teuber, Christoph Antoni, Stefan Zeuzem, Thomas Discher, Markus Cornberg, et al. 2019. “FRI-208-Predictors of Treatment Response during Addition of Pegylated Interferon Alfa-2a to an Onging Nucleos (t)Id Treatment in Chronic Hepatitis B: Results from the PADD-ON Trial.” Journal of Hepatology 70 (April): e485. doi:10.1016/S0618-8278(19)30953-3.